Division of Biological Sciences, University of California, San Diego, CA 92093, USA.
Division of Biological Sciences, University of California, San Diego, CA 92093, USA.
Trends Immunol. 2022 Jul;43(7):500-502. doi: 10.1016/j.it.2022.05.003. Epub 2022 Jun 5.
Emerging immunotherapies offer a new hope for cancer patients but are not always effective even when a tumor is recognized by the immune system. Baldominos and colleagues address this challenge by characterizing a resilient niche of metabolically unique quiescent cancer cells (QCCs) that resist T cell-mediated control.
新兴的免疫疗法为癌症患者带来了新的希望，但即使肿瘤被免疫系统识别，这些疗法也并不总是有效。Baldominos 及其同事通过描述代谢上独特的静止癌细胞（QCC）的弹性小生境来应对这一挑战，这些 QCC 能够抵抗 T 细胞介导的控制。
